The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis

Table 2

VAD-treated vs. T-VAD-treated MM patients.

Study	Stage	Patients		Age (years)	Comparison		Trial conditions and units
	I/II/III	Control (M/F)	Exp (M/F)	Control/Exp	Control	Exp
Cong et al., 2012 [27]	4/12/30	23	23	65/68	VAD	T-VAD	ELISA; VEGF (ng/L)
Yang et al., 2015 [29]	6/26/58	43 (23/20)	47 (25/22)	67.4/66.9	VAD	T-VAD	ELISA; VEGF (pg/ml)
Long et al., 2015 [30]	0/19/71	45 (26/19)	45 (27/18)	56.4/55.3	VAD	T-VAD	ELISA; VEGF (ng/L)
Yuan et al., 2004 [31]	10/31/12	30 (18/12)	23 (15/8)	62/61	VAD	T-VAD	ELISA; VEGF (ng/L)
Liu et al., 2016 [32]	0/24/26	25 (12/13)	25 (13/12)	67.1/67.1	VAD	T-VAD	ELISA; VEGF (pg/ml)
Tan et al.,; 2008 [33]	11/33/12	28 (16/12)	28 (15/13)	62/61	VAD	T-VAD	ELISA; VEGF (ng/L)
Yang et al., 2005 [34]	0/ 8/76	45 (31/14)	39 (29/10)	51.5/52.3	VAD	T-VAD	ELISA; VEGF (ng/L)
Dong, 2004 [28]	7/8/19	6	6	31.3/49.8	VAD	T-VAD	ELISA; VEGF (ng/L)